Greene, Harold

71-year-old with BCLC-B hepatocellular carcinoma (3 lesions, largest 4.2cm), AFP 890 ng/mL, Child-Pugh A6, HCV-related cirrhosis (SVR achieved). TACE vs. systemic therapy (atezolizumab/bevacizumab) as initial approach. Evaluate transplant candidacy with potential downstaging protocol.

TACE eligibility with multinodular BCLC-B disease — treatment schedule optimization.

Liver transplant candidacy with Milan criteria downstaging protocol.

TACE eligibility with multinodular BCLC-B disease — treatment schedule optimization.

Liver transplant candidacy with Milan criteria downstaging protocol.

Liver transplant candidacy with Milan criteria downstaging protocol.

TACE eligibility with multinodular BCLC-B disease — treatment schedule optimization.

Liver transplant candidacy with Milan criteria downstaging protocol.

Atezolizumab + bevacizumab first-line vs. lenvatinib given portal hypertension and variceal bleeding risk.

Liver transplant candidacy with Milan criteria downstaging protocol.

Liver transplant candidacy with Milan criteria downstaging protocol.

Atezolizumab + bevacizumab first-line vs. lenvatinib given portal hypertension and variceal bleeding risk.

TACE eligibility with multinodular BCLC-B disease — treatment schedule optimization.

TACE eligibility with multinodular BCLC-B disease — treatment schedule optimization.

TACE eligibility with multinodular BCLC-B disease — treatment schedule optimization.

Atezolizumab + bevacizumab first-line vs. lenvatinib given portal hypertension and variceal bleeding risk.